Adding baricitinib to standard-of-care topical corticosteroids significantly improved disease severity, they said. Baricitinib is approved for the treatment of adults with moderately to severely active rheumatoid arthritis in more than 60 countries.
Price: 81.91, Change: -3.65, Percent Change: -4.27
|Q3 and 2020 Full Year Earnings Estimate for NovoCure...|
|2019, and Q3 Estimates for Nucor Corp Scaled Down bu...|
|Matador Resources' 2019, 2020 Full Year Earnings Est...|
|Analysts' Drop New Relic's 2020, 2021 Earnings Estim...|
|MasterCraft Boat Holdings' 2020, 2021, and Q3 Earnin...|